Latest Hotspot

Bristol Myers Squibb Expands Portfolio with Purchase of Leading Radiopharmaceutical Company RayzeBio

2 January 2024
3 min read

Pharmaceutical giant Bristol Myers Squibb has entered into a binding merger contract to purchase biotech firm RayzeBio, Inc. The deal sets the purchase price at $62.50 for each share, entirely in cash transactions, which sums up to an overall value of around $4.1 billion in equity. When considering the cash holdings that Bristol Myers Squibb is expected to inherit, the net acquisition cost stands at about $3.6 billion. This strategic move has received full backing from the governing bodies of both corporations, with unanimous consent achieved from the Board of Directors at Bristol Myers Squibb as well as RayzeBio.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Operating in the domain of clinical-stage radiopharmaceutical treatments, RayzeBio is positioned at the forefront of innovation involving actinium-based RPTs. The company is currently advancing a suite of unique drug development initiatives which may lead the market as first-in-class and best-in-class offerings. Their developmental thrust is primarily directed toward solid tumor therapies, with specific applications for gastroenteropancreatic neuroendocrine tumors, small cell lung cancer, hepatocellular carcinoma, and several other forms of cancer.

"Joining forces with RayzeBio represents a significant step in broadening our cancer treatment portfolio, introducing a unique technology and collection of drug candidates. This move is poised to underpin our expansion in the latter half of this decade and into the future," commented Christopher Boerner, Ph.D., the Chief Executive Officer at Bristol Myers Squibb.

Expressing optimism about the alliance, Ken Song, M.D., the President and CEO of RayzeBio, stated, "The established expertise of Bristol Myers Squibb within the oncology sector and their profound skills in growing, commercializing, and manufacturing on an international scale positions them as the premier collaborator for RayzeBio during this pivotal phase. I am eager to witness the achievements our team will realize within the Bristol Myers Squibb environment."

A primary focus of RayzeBio's lineup is RYZ101, designed to target somatostatin receptor 2 (SSTR2), which finds increased expression in GEP-NETs and extensive stage small cell lung cancer. There is an ongoing Phase 3 clinical trial actively recruiting subjects in order to assess RYZ101's effectiveness in patients with detectable SSTR-positive GEP-NETs, who have already undergone treatments with lutetium-177 tagged somatostatin analogs.

RayzeBio has recently shared preliminary outcomes from the ACTION-1 Phase 1b clinical trial, indicating promising signs of efficacy and safety. Another Phase 1b trial is in progress to determine the viability of RYZ101 as an initial treatment modality for ES-SCLC, in conjunction with the current standard treatment protocols.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of December 30, 2023, there are 46 investigational drugs for the SSTR2 target, including 60 indications, 53 R&D institutions involved, with related clinical trials reaching 303, and as many as 1697 patents.

RYZ-101 is a hormone, radiopharmaceutical, and diagnostic agent that targets SSTR2. It has shown potential in treating various neoplasms, respiratory diseases, digestive system disorders, and endocrinology and metabolic diseases. 

图形用户界面, 文本

描述已自动生成

Exploring TLR agonists: What They Are and How to Keep Up with the Latest Advances
Exploring TLR agonists: What They Are and How to Keep Up with the Latest Advances
2 January 2024
TLR agonists are substances that activate the Toll-like receptor, enhancing the immune response against pathogens.
Read →
Coherus announces FDA approval for UDENYCA ONBODY™, a cutting-edge pegfilgrastim-cbqv delivery technology
Latest Hotspot
3 min read
Coherus announces FDA approval for UDENYCA ONBODY™, a cutting-edge pegfilgrastim-cbqv delivery technology
2 January 2024
Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.
Read →
What are the types of protein sulfation and their implications in protein-protein interactions?
"What" Series
2 min read
What are the types of protein sulfation and their implications in protein-protein interactions?
2 January 2024
Protein sulfation is a post-translational modification, where a sulfate group gets added to a specific amino acid residue in a protein.
Read →
Research findings on Chugai's innovative multispecific antibody DONQ52, aimed at treating Celiac Disease
Latest Hotspot
3 min read
Research findings on Chugai's innovative multispecific antibody DONQ52, aimed at treating Celiac Disease
2 January 2024
Chugai Pharma announced preclinical results for their antibody, DONQ52, published in Nature Communications.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.